Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition

Authors:

Abstract
Taste dysfunction, or dysgeusia, is a common side effect of many cancer drugs. Dysgeusia is often reported by people treated with anti-angiogenic tyrosine kinase inhibitors (TKIs), which inhibit receptor tyrosine kinases (RTKs). However, the mechanisms by which TKIs cause dysgeusia are not understood, as the role of RTKs in adult taste homeostasis is unknown. Here, we find that treating adult mice with the TKI cabozantinib shifts the fate of differentiating functional taste cell subtypes within taste buds. Through behavioral assays, we find this cell fate shift leads to blunted responses to sweet tastants in cabozantinib-treated mice. Finally, we show that inducible knockout of the RTK KIT, which is inhibited by cabozantinib, phenocopies taste cell fate shifts induced by TKI treatment. Our results establish KIT as a regulator of taste cell homeostasis and suggest that KIT inhibition may underlie TKI-induced dysgeusia in humans.
All Related Versions
Funding Information
  • National Institutes of Health (T32GM141742)
  • National Institutes of Health (R01AI167923)
  • National Institutes of Health (R21CA236480)
  • National Institutes of Health (R01DC012383)
  • National Institutes of Health (R01DC018489)
  • National Institutes of Health (R01DC021865)
  • National Institutes of Health (F31DC020634-01)
  • University of Colorado

This publication has 113 references indexed in Scilit: